Shishuka Malhotra
Psychiatry · Canton, OHNPI 1578582649
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (35.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Eisai Inc. at 39.3% of the total. Reporting peaked in 2019 at $1,811 and has fallen 96.1% since, to $71 in 2025.
Across 62 payments — averaging $62.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$2K
- Boehringer Ingelheim International GmbH$1K
- Vanda Pharmaceuticals Inc.$254
- AbbVie$150
- Alkermes, Inc.$138
- Biogen$71
- plus $347 from 11 others
Across 1,966 payments — averaging $7760.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3.3M
- AbbVie$1.6M
- Vanda Pharmaceuticals Inc.$1.5M
- Sage Therapeutics, LLC$1.4M
- Boehringer Ingelheim$1.1M
- Sumitomo Pharma America, Inc.$945K
- plus $5.5M from 30 others
What the payments were for
- Speaking & faculty fees$1,38836%
- Travel & lodging$1,20231%
- Food & beverage$1,28133%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 12 | $1,523 |
| Boehringer Ingelheim International GmbH | 4 | $1,388 |
| Vanda Pharmaceuticals Inc. | 13 | $254 |
| AbbVie(2 entities) | 9 | $150 |
| Alkermes, Inc. | 2 | $138 |
| Biogen | 1 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Noven Therapeutics, LLC | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $42 |
| Shire North American Group Inc | 2 | $28 |
| Neuronetics, Inc. | 2 | $27 |
| Lundbeck LLC | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Indivior Inc. | 1 | $17 |
| Orexo US, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Belviq$1,266
How this compares
$3,871 in reported general payments places this provider in the 85th percentile of 1,119 psychiatry providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Zolpidem Tartrate | 18 | $104 |
| Lorazepam | 15 | $19 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Canton
- Pradeep ManudhaneCanton$1.5M
- Henry NasrallahCincinnati$3.8M
- Fred RomeoColumbus$2.3M
- Amita PatelDayton$2.1M
- Michael SaribalasColumbus$1.2M
- Kevin WareColumbus$1.1M
- Binit ShahCleveland$913K
- Paul KeckCincinnati$739K
- Ali MelhemSteubenville$681K
- Tracey SkaleCincinnati$674K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.